on May 22, 2003
Published online before print May 22, 2003, doi: 10.1161/01.STR.0000074032.64049.47
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 10, 2003
From Medical Clinic II (C.D.G., S.K., S.F.-M., C.S., S.E., D.R., A.Y., J.L., W.D.G.), the Clinic of Neurology (R.H., B.N.), and the Clinic of Neuroradiology (B.T.), Friedrich-Alexander-University, Erlangen-Nuremberg, and the Heart Center Dresden (A.S.), Dresden, Germany. * To whom correspondence should be addressed. E-mail: Christoph.Garlichs{at}rzmail.uni-erlangen.de.
Background and Purpose--Inflammation and hypercoagulability contribute to the development of acute cerebral ischemia. Both can be mediated by the CD40 system. This study investigated whether the CD40 system and related mediators are upregulated in patients with transient ischemic attack (TIA) or stroke. Methods--Seventeen patients with TIA, 60 patients with complete stroke, and 15 control subjects were investigated. CD154 and P-selectin were analyzed on platelets and CD40 on monocytes during and 3 months after acute cerebral ischemia by double-label flow cytometry. Blood concentrations of soluble CD154 and monocyte chemoattractant protein-1 (MCP-1) were evaluated. Results--Our main findings are as follows: (1) patients with acute cerebral ischemia showed a significant increase of CD154 on platelets and CD40 on monocytes compared with controls; (2) plasma levels of soluble CD154 were significantly higher in these patients; (3) these patients had significantly higher numbers of prothrombotic platelet-monocyte aggregates; (4) the chemoattractant MCP-1 was significantly elevated in cerebral ischemia; and (5) at 3 months' follow-up, upregulation of CD154 still persisted in patients with previous acute cerebral ischemia. Conclusions--Patients with acute cerebral ischemia show upregulation of the CD40 system, which might contribute to the known proinflammatory, proatherogenic, and prothrombotic milieu found in these patients.
Accepted on January 27, 2003
Upregulation of CD40-CD40 Ligand (CD154) in Patients With Acute Cerebral Ischemia
C. D. Garlich*;
Key words: blood platelets • CD40 • CD154 • cerebral ischemia • inflammation
This article has been cited by other articles:
 |
|
 |
|
  J. Smout, A. Dyker, M. Cleanthis, G. Ford, P. Kesteven, and G. Stansby Platelet Function Following Acute Cerebral Ischemia Angiology, June 1, 2009; 60(3): 362 - 369. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Klohs, M. Grafe, K. Graf, J. Steinbrink, T. Dietrich, D. Stibenz, P. Bahmani, G. Kronenberg, C. Harms, M. Endres, et al. In Vivo Imaging of the Inflammatory Receptor CD40 After Cerebral Ischemia Using a Fluorescent Antibody Stroke, October 1, 2008; 39(10): 2845 - 2852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Choudhury, I. Chung, N. Panja, J. Patel, and G. Y. H. Lip Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation: Relationship to Soluble P-Selectin, Stroke Risk Factors, and Risk Factor Intervention Chest, September 1, 2008; 134(3): 574 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rodriguez-Yanez, J. Agulla, R. Rodriguez-Gonzalez, T. Sobrino, and J. Castillo Review: Statins and stroke Therapeutic Advances in Cardiovascular Disease, June 1, 2008; 2(3): 157 - 166. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Li, J. M. Sanders, M. H. Bevard, Z. Sun, J. W. Chumley, E. V. Galkina, K. Ley, and I. J. Sarembock CD40 Ligand Promotes Mac-1 Expression, Leukocyte Recruitment, and Neointima Formation after Vascular Injury Am. J. Pathol., April 1, 2008; 172(4): 1141 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Choudhury, B. Freestone, J. Patel, and G. Y. H. Lip Relationship of Soluble CD40 Ligand to Vascular Endothelial Growth Factor, Angiopoietins, and Tissue Factor in Atrial Fibrillation: A Link Among Platelet Activation, Angiogenesis, and Thrombosis? Chest, December 1, 2007; 132(6): 1913 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ferro, L. Loffredo, L. Polimeni, F. Fimognari, P. Villari, P. Pignatelli, V. Fuster, and F. Violi Soluble CD40 Ligand Predicts Ischemic Stroke and Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2763 - 2768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hocher, L. Liefeldt, T. Quaschning, P. Kalk, R. Ziebig, M. Godes, K. Relle, G. Asmus, and J.-P. Stasch Soluble CD154 Is a Unique Predictor of Nonfatal and Fatal Atherothrombotic Events in Patients Who Have End-Stage Renal Disease and Are on Hemodialysis J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1323 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Y.H. Lip, J. V. Patel, E. Hughes, and R. G. Hart High-Sensitivity C-Reactive Protein and Soluble CD40 Ligand as Indices of Inflammation and Platelet Activation in 880 Patients With Nonvalvular Atrial Fibrillation: Relationship to Stroke Risk Factors, Stroke Risk Stratification Schema, and Prognosis Stroke, April 1, 2007; 38(4): 1229 - 1237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Baird The Forgotten Lymphocyte: Immunity and Stroke Circulation, May 2, 2006; 113(17): 2035 - 2036. [Full Text] [PDF]
|
|
|
|
|
|
G. Yilmaz, T. V. Arumugam, K. Y. Stokes, and D. N. Granger Role of T Lymphocytes and Interferon-{gamma} in Ischemic Stroke Circulation, May 2, 2006; 113(17): 2105 - 2112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Weerasinghe, T. Athanasiou, P. Philippidis, J. Day, K. Mandal, O. Warren, J. Anderson, and K. Taylor Platelet-monocyte pro-coagulant interactions in on-pump coronary surgery Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 312 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kobayashi, Y. Nishimura, T. Shimada, S. Yoshimura, Y. Funada, M. Satouchi, and M. Yokoyama Effect of Continuous Positive Airway Pressure on Soluble CD40 Ligand in Patients With Obstructive Sleep Apnea Syndrome Chest, March 1, 2006; 129(3): 632 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chakrabarti, S. Varghese, O. Vitseva, K. Tanriverdi, and J. E. Freedman CD40 Ligand Influences Platelet Release of Reactive Oxygen Intermediates Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2428 - 2434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ishikawa, T. Vowinkel, K. Y. Stokes, T. V. Arumugam, G. Yilmaz, A. Nanda, and D. N. Granger CD40/CD40 Ligand Signaling in Mouse Cerebral Microvasculature After Focal Ischemia/Reperfusion Circulation, April 5, 2005; 111(13): 1690 - 1696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Ritter, K. M. Stempel, B. M. Coull, and P. F. McDonagh Leukocyte-Platelet Aggregates in Rat Peripheral Blood After Ischemic Stroke and Reperfusion Biol Res Nurs, April 1, 2005; 6(4): 281 - 288. [Abstract] [PDF]
|
|
|
|
|
|
S. Novo, S. Basili, R. Tantillo, A. Falco, V. Davi, G. Novo, E. Corrado, and G. Davi Soluble CD40L and Cardiovascular Risk in Asymptomatic Low-Grade Carotid Stenosis Stroke, March 1, 2005; 36(3): 673 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. DeGraba Immunogenetic Susceptibility of Atherosclerotic Stroke: Implications on Current and Future Treatment of Vascular Inflammation Stroke, November 1, 2004; 35(11_suppl_1): 2712 - 2719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. G. Nadareishvili, H. Li, V. Wright, D. Maric, S. Warach, J. M. Hallenbeck, J. Dambrosia, J. L. Barker, and A. E. Baird Elevated pro-inflammatory CD4+CD28- lymphocytes and stroke recurrence and death Neurology, October 26, 2004; 63(8): 1446 - 1451. [Abstract] [Full Text] [PDF]
|
|